Skip to main content
Back to timeline
BoltzSource publication:

Boltz raises $110M Series A: six of the world's 20 largest pharma companies are signed, and paying-customer molecular token use is up 50-fold since June

Synopsis

Boltz announced a $110 million Series A led by Bessemer Venture Partners, with all existing investors doubling down. The company says it has signed six of the world's 20 largest pharma companies, including Pfizer, GSK, Takeda and BMS, and that molecular token usage among paying customers has grown 50-fold since June. The funding is meant to deepen compute and data investment, meet partner demand and expand the team.

Source-provided article image: Announcing our Series A
Boltz

Interpretation

Boltz closed a $110 million Series A led by Bessemer Venture Partners, with existing investors Andreessen Horowitz, Amplify Partners, Zetta Venture Partners and Obvious Ventures all doubling down, joined by new investors including Greycroft, F-Prime Capital, Hummingbird and Benchling. Boltz describes itself as having grown in just over a year from a small group of MIT researchers to a team of 40 scientists and engineers. The company says it has signed six of the world's 20 largest pharma companies, including Pfizer, GSK, Takeda and BMS, which use its models through the Boltz Lab platform.

The Boltz Lab platform puts the company's molecular models in the hands of any scientist or AI agent, spanning target validation through lead optimization. The company says its bet was that token usage for biomolecular design would grow exponentially as in other areas of AI, and that the release of BoltzMol-1 and BoltzProt-1 accelerated that momentum. The company says molecular tokens processed for its users have grown 50-fold since June, and that thousands of scientists signed up within weeks of the platform's January launch.

Boltz says that with BoltzMol-1 and BoltzProt-1 it discovered small-molecule hits and designed protein binders for a majority of the challenging targets it pursued. The company says this took a fraction of the time and cost that traditional methods or previous models would have required. The claim is the company's own account and gives no target count, success rate or comparison against a specific baseline.

Perspective

This item is for researchers and engineers following AI drug-development commercialization; it covers a company-issued financing and business update, and the amount, signed pharma companies, token growth multiple and model outputs all come from Boltz's own account.

The company says its upcoming models already show substantial improvements in the quality of generated molecules but gives no metrics; it says the long-term goal of going from a therapeutic hypothesis to a human-ready molecule still requires further model advances and substantial investment in compute and data.